Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-24

Study Completion Date

2022-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paclitaxel, a widely used chemotherapeutic agent, is associated with several well-known side effects including neuropathy (weakness, numbness and pain) and generalized body aches. The latter has recently been described as paclitaxel-associated acute pain syndrome (P-APS) and often occurs in the first three to four days after administration. It affects about 58-90% of patients. Currently, the mechanism of P-APS is unknown, and there is no standard of care to treat it. However, an intervention with both anti-inflammatory as well as neuroprotective properties would be an ideal candidate for testing in the prevention of P-APS and subsequent development of peripheral neuropathy. Previous studies have suggested that omega-3 fatty acids may act as neuroprotective agents, and there are no currently documented safety concerns with their combined use with paclitaxel.

Therefore, this randomized pilot clinical trial will determine whether omega-3 fatty acids can treat pain in patients with breast or ovarian cancer receiving paclitaxel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy

NCT01385137

Arthralgia Breast Cancer Pain

COMPLETED PHASE3

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764

Ductal Breast Carcinoma in Situ Lobular Breast Carcinoma in Situ Male Breast Cancer +6 more

COMPLETED PHASE2

Breast, Omega 3 Free Fatty Acid, Ph 0

NCT02996240

Breastcancer

COMPLETED NA

Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer

NCT00114296

Breast Cancer

UNKNOWN NA

Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer

NCT03383835

Breast Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One mechanism proposed for P-APS is an early inflammatory process characterized by macrophage activation in both the dorsal root ganglia and peripheral nerve occurring shortly after paclitaxel therapy. Morphologic alterations in DRG satellite cells have been noted and upregulation of proinflammatory cytokines have been hypothesized as early events in the development of neuropathy. Therefore, it is possible that paclitaxel-induced neuropathic pain may be mediated by pro-inflammatory cytokines. If P-APS and chronic neuropathy are indeed part of a continuum, the inflammatory pathway would be a reasonable target for therapy. While the mechanism of how paclitaxel leads to the development of neuropathy is still not understood, it has been hypothesized that its microtubule-stabilizing effects disrupt axonal transport. Intervention with an agent that is both anti-inflammatory as well as neuroprotective is therefore worth exploring.

Long chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are common dietary supplements. They have well established anti-inflammatory properties which serve as the basis for their use in therapeutic trials in inflammatory conditions. Omega -3 fatty acids consumption can attenuate the production of pro-inflammatory metabolites. In addition, it can generate local mediators that facilitate resolution of inflammation. Thus, if P-APS is indeed mediated by inflammation, the anti-inflammatory activity of omega 3 fatty acids may be one mechanism to prevent P-APS. Additionally, given its well established safety profile, it may be an attractive alternative to NSAIDS.

A dose of at least 2.7 g/day of EPA and DHA have been reported to have analgesic effects in inflammatory conditions. The dose of 4 g/day is an FDA-approved dose of omega 3 fatty acids (Lovaza) for the treatment of hypertriglyceridemia and has a well-documented toxicity profile. On the basis of this, a dose of 4 g/day was selected for this study. Lovaza (omega-3-acid ethyl esters) capsules will be used. Each 1-gram capsule contains approximately 465 mg EPA and 375 mg DHA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Ovarian Neoplasm Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (Omega-3 fatty acid)

Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.

The capsules may be administered either once daily or as 2 capsules two times daily.

Group Type EXPERIMENTAL

Omega-3 fatty acid

Intervention Type DIETARY_SUPPLEMENT

Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.

Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).

Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA).

Paclitaxel

Intervention Type DRUG

Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.

Arm II (placebo)

Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.

The capsules may be administered either once daily or as 2 capsules two times daily.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.

Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)

Paclitaxel

Intervention Type DRUG

Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 fatty acid

Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.

Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).

Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA).

Intervention Type DIETARY_SUPPLEMENT

Placebo

Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.

Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)

Intervention Type DIETARY_SUPPLEMENT

Paclitaxel

Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fish oil n-3 fatty acid O3FA Lovaza Taxol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients have a diagnosis of breast cancer or ovarian cancer
* Patients are scheduled to receive weekly paclitaxel at 70-90 mg/m\^2 for a minimum of 2 months; 3 out of 4 weeks is allowed
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2
* Patients must not have taken omega-3-fatty acid supplements within the past 1 month prior to registration and must agree to refrain from use of omega- 3 fatty acid supplements from sources outside the study
* Patients must not be on nonsteroidal anti-inflammatory drugs (NSAIDS) or aspirin for at least 1 week prior to registration; NSAIDS or aspirin are allowed after enrollment
* Patients must not have received any other analgesics (opiates and tramadol) 1 week prior to registration; analgesics (opiates and tramadol) are allowed after enrollment
* Patients must have the ability to complete questionnaires by themselves or with assistance
* Patients must not be on anticoagulation medication (heparin/ warfarin) within 28 days prior to registration, because of increased risk of bleeding
* Concurrent treatment with carboplatin +/- bevacizumab is allowed
* Concurrent treatment with human epidermal growth factor receptor (Her2 neu) targeted therapy is allowed

Exclusion Criteria

* Known allergy to omega 3 fatty acids, fish or shellfish
* Pre-existing diagnosis of peripheral neuropathy
* Diagnosis of fibromyalgia
* Concurrent planned neutrophil colony stimulating factor therapy
* Prior exposure to paclitaxel within the last 6 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No